Background: Anal cancer is a relatively less common gastrointestinal cancer, with common sites of distant metastasis being para-aortic nodes, liver, lungs, and skin. Intraocular metastasis from anal squamous cell carcinoma is an extremely rare occurrence with no reported cases so far. Case Description: We present a case of a 70-year-old male with a past medical history of metastatic anal squamous cell carcinoma who presented to the oncology clinic with complaints of sudden onset complete vision loss in his right eye. The patient was then referred to a retina specialist and was found to have a posterior choroidal tumor that raised concerns of a primary uveal melanoma vs. metastatic spread from his known metastatic anal squamous cell carcinoma. Given the severity of his symptoms and diagnostic uncertainty, he underwent right eye enucleation and prosthesis placement. Histopathologic evaluation of the enucleated specimen confirmed the diagnosis of metastatic carcinoma consistent with anal carcinoma. Conclusions: This case presents the exceptionally rare phenomenon of intraocular metastasis from a primary anal squamous cell carcinoma. Per our literature review, this is the first reported case of such an occurrence, which adds to the clinical complexity of this case in terms of timely diagnosis, effective treatment modalities and prognosis. In these cases, early recognition and diagnosis is critical, as intraocular metastasis significantly affects quality of life as well as overall prognosis. Therefore, through this case report, we aim to highlight the rare intraocular presentation of metastatic anal cell carcinoma, so that clinicians maintain a broad differential diagnosis when evaluating new ophthalmic symptoms in patients with anal cancer.
Head and neck squamous cell carcinoma (HNSCC) remains a significant global health burden with limited survival improvement in locally advanced disease despite multimodal therapy. Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway have demonstrated substantial clinical benefit in recurrent or metastatic HNSCC, establishing PD-1 blockade as a standard of care. Similar approaches in locally advanced disease, including concurrent administration with chemoradiotherapy or use in the adjuvant setting, have not demonstrated improvement in survival outcomes across multiple randomized trials. Perioperative strategies incorporating neoadjuvant and adjuvant checkpoint inhibition have shown improved event-free and disease-free survival in resectable disease. Meta-analyses of concurrent and adjuvant approaches confirm limited benefit in unselected populations, with modest improvements restricted to biologically defined subgroups. Trial outcomes across disease settings demonstrate a consistent pattern in which therapeutic efficacy varies despite the use of similar agents. Rather than simply summarizing these clinical findings, this review integrates evidence across recurrent/metatstatic, unresected locally advanced and perioperative disease settings into a biologically focused framework to help explain the varying efficacies of immune checkpoint inhibition in HNSCC. Current evidence indicates that the effectiveness of immunotherapy in HNSCC is determined by the biologic context of treatment, including tumor antigen availability, host immune competence, and timing of immune activation. Administration of checkpoint blockade in the presence of intact tumor antigen and preserved immune function is associated with improved outcomes, whereas treatment delivered during or after cytotoxic therapy is limited by lymphopenia and reduced antigen exposure. By synthesizing randomized clinical evidence through this biologic framework, the review provides a conceptual perspective that may help explain previous trial outcomes and inform future biomarker-driven patient selection and treatment sequencing. Optimization of immunotherapy in HNSCC will depend on the integration of immune activation with disease context rather than an escalation of therapeutic intensity.